Skip to main content

Table 2 Treatment characteristics

From: Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases

Characteristics

All Patients

(N = 18) n (%)

Size of LN metastases, cm (median, (range))

1.95 (0.8, 6.2)

GTV volume, cm3 (median, (range))

8.4 (0.7, 67.8)

PTV volumes, cm3 (median, (range))

34.8 (6.5, 162.2)

SBRT dose (BED10 Equivalent)a

 60 Gy/8 (105 Gy)

1 (5.6)

 50 Gy/10 (75 Gy)

2 (11.1)

 40 Gy/5 (72 Gy)

5 (27.8)

 35 Gy/5 (59.5 Gy)

8 (44.4)

 31 Gy/4 (55 Gy)

1 (5.6)

 33 Gy/5 (54.8 Gy)

1 (5.6)

 Prescribed BED10, Gy (median, (range))

59.5 (54.8, 105)

 D95b BED10, Gy (median, (range))

56.6 (29.8, 72.0)

 D95 BED10 > 70 Gy

4 (22.2)

 D95 BED10 > 50 Gy

12 (66.7)

PTV V100, %

 Mean ± SD

78.6 ± 22.4

 Median (Range)

90.0 (21.0, 95.2)

PTV V95, %

 Mean ± SD

87.5 ± 14.7

 Median (Range)

95.6 (60.4, 100)

PTV V90, %

 Mean ± SD

91.7 ± 10.8

 Median (Range)

97.8 (67.6, 100)

  1. aBED10: Biological Equivalent Dose assuming α/β of 10
  2. bD95: Minimum dose to 95% of PTV